- Home
- AKTX vs CRIS Comparison
AKTX vs CRIS Comparison
Compare AKTX & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- CRIS
- Stock Information
- Founded
- AKTX N/A
- CRIS 2000
- Country
- AKTX United States
- CRIS United States
- Employees
- AKTX N/A
- CRIS N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AKTX Health Care
- CRIS Health Care
- Exchange
- AKTX Nasdaq
- CRIS Nasdaq
- Market Cap
- AKTX 29.5M
- CRIS 31.2M
- IPO Year
- AKTX N/A
- CRIS 2000
- Fundamental
- Price
- AKTX $0.99
- CRIS $3.45
- Analyst Decision
- AKTX
- CRIS Strong Buy
- Analyst Count
- AKTX 0
- CRIS 3
- Target Price
- AKTX N/A
- CRIS $23.00
- AVG Volume (30 Days)
- AKTX 91.8K
- CRIS 66.1K
- Earning Date
- AKTX 02-15-2025
- CRIS 02-06-2025
- Dividend Yield
- AKTX N/A
- CRIS N/A
- EPS Growth
- AKTX N/A
- CRIS N/A
- EPS
- AKTX N/A
- CRIS N/A
- Revenue
- AKTX N/A
- CRIS $10,259,000.00
- Revenue This Year
- AKTX N/A
- CRIS N/A
- Revenue Next Year
- AKTX N/A
- CRIS N/A
- P/E Ratio
- AKTX N/A
- CRIS N/A
- Revenue Growth
- AKTX N/A
- CRIS 0.44
- 52 Week Low
- AKTX $0.90
- CRIS $3.43
- 52 Week High
- AKTX $4.40
- CRIS $17.49
- Technical
- Relative Strength Index (RSI)
- AKTX 31.38
- CRIS 38.10
- Support Level
- AKTX $0.95
- CRIS $3.42
- Resistance Level
- AKTX $1.13
- CRIS $4.25
- Average True Range (ATR)
- AKTX 0.15
- CRIS 0.31
- MACD
- AKTX 0.02
- CRIS -0.03
- Stochastic Oscillator
- AKTX 15.15
- CRIS 13.83
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.